Exit Options for John Hancock Bond and Corporate Finance Group: Hanover Communications In... - 28 Strategic Investors

View x

Israeli biotech company KAHR raises $12 million Series B funds

Drug development company KAHR Medical Ltd has raised $12 million in a Series B financing round from new investors Korea Investment Partners, Mirae Asset Venture Investment and DSC Investment, along with an existing investor, Flerie Invest AB. The Jerusalem-based developer of cancer and auto-immune treatments plans to use the new financing primarily to fund the clinical development of KAHR’s lead product, KAHR-102, which recently received regulatory approval in Israel to initiate a Phase-I/IIa trial in lymphoma, as well as pre-clinical development of KAHR-101 and new pipeline programs. RM Global Partners advised KAHR on the financing. KAHR was represented by Pearl Cohen Zedek Latzer Baratz law firm.

Tags:

VC Deals,biotech,DSC Investment,Flerie Investment,KAHR Medical,Korea Investment Partners,Mirae Asset Venture Investment,RM Global Partners